Dublin, March 27, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/7xzqrp/north_american) has announced the addition of the "North American Intrauterine Contraceptive Devices (IUCD) Market by Type (Female Contraceptive devices, Male Contraceptive devices) - Forecast to 2019" report to their offering.
The North America intrauterine contraceptive devices market is estimated to grow at a CAGR of 0.3% from 2014 to 2019.
The growth of the intrauterine contraceptive devices market is driven by factors such as increasing rate of unplanned pregnancies, effective contraception and less side effects of IUCD, implementation of the Affordable Care Act (ACA), rising initiatives of private firms directed towards reducing expenses related to abortion, funds/grants for IUCD products, and technological advancements.
However, high costs of treatment, threat of pelvic inflammatory infection (PID), threat of ectopic pregnancy, high rate of complications during unplanned pregnancy, and the need for compulsory assistance of medical professionals hamper the growth of the IUCD market. Moreover, the rising number of players in this segment and technological advancements create growth opportunities for the North America intrauterine contraceptive devices market in these regions.
In this report, the North America intrauterine contraceptive devices market has been broadly classified on the basis of types, which includes Hormonal IUCD and Copper IUCD. The hormonal IUCD market segment accounted for the largest market share of 83.4% of the North American intrauterine contraceptive devices market. Factors such as safety, easy removal, lighter periods, and the increasing adoption of hormonal IUD products such as Mirean and Skyla in the U.S. drive the growth of this market.
Geographically, the U.S. is estimated to command the largest share of 93.0% of the North America intrauterine contraceptive devices market in 2014, followed by Canada. The intrauterine contraceptive devices market in the U.S. is primarily driven by the Affordable Care Act and technological advancements. However, stringent regulatory and reimbursement policies in the U.S. and the threat of PID infection hamper the growth of the intrauterine contraceptive devices market in this region.
The North America intrauterine contraceptive devices market is a competitive market with a number of market players. As of 2014, the North America intrauterine contraceptive devices market is estimated to be dominated by Bayer HealthCare AG (A subsidiary of BAYER AG) (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Actavis Plc. (Ireland), and Medicines360 (Ireland). New product launches & partnerships, agreements, collaborations, and joint ventures are the major strategies adopted by most market players to achieve growth in the North America intrauterine contraceptive devices market.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Market Overview
5 North America Intra-Uterine Contraceptive Devices Market, By Type
6 North America Intra-Uterine Contraceptive Devices Market, By Product
6.5 Pipeline Products
7 North America Intra-Uterine Contraceptive Devices Market,By Geography
8 North America Intra-Uterine Contraceptive Devices Market: Competitive Landscape
9 North America Intra-Uterine Contraceptive Devices Market, By Company
- Actavis Plc
- Bayer Healthcare Ag (Subsidiary Of Bayer Ag)
- Medicines360
- Medisafe Distribution Inc.
- Pace Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Trimedic Supply Network Ltd.
For more information visit http://www.researchandmarkets.com/research/7xzqrp/north_american